H. Eric Cannon, PharmD, FAMCP: Money can’t solve all our problems, but it sure helps. Can you afford your co-pays? Poverty is definitely playing into this. Homeless people [are affected]. We’re starting to work with populations that have recently been discharged from prison. There are people who don’t feel accepted. That acceptance goes across a lot of levels. If I found a physician or a therapist, but I don’t feel accepted or I don’t feel that it’s an inclusive environment, I might not keep going. That plays a role in how a patient feels. Finding ways to be more inclusive is critical for all of us.
Michael Rothrock, MBA, MHA: This is a continuing theme of our last couple of topics. We’ve [spoken] about the socioeconomic status of individuals who are the most challenging to identify and get access and care to, based on their lower income levels. At the end of the day, it comes down to education, affordability, access to care, promotion, and awareness through the workforce and your own internal HR [human resources] departments to say that there are self-help opportunities and ways to get in touch with providers or caregivers to assist you if you or a family member are experiencing symptoms of depression.
This holistic approach becomes much more magnified, and we’re much more aware as a society. We went through 2-plus years of COVID-19, and we’re trying to find the best way to [reach] these patients on a regular basis, or at least provide them the help or care they need so they can invest in themselves. As Dr Cannon mentioned, affordability is one thing. If they can’t afford the co-pays, that’s going to be a challenge. But other ways of finding care through local communities—self-help books, manufacturer-sponsored programs, church groups, even your own colleagues and friends—is something we need to see as an opportunity to [reach] these patients more frequently.
Transcript edited for clarity.
Social Determinants of Health in MDD
Key social determinants affecting MDD are evaluated by Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP.
EP: 1.Unmet Needs in Treatment of MDD
EP: 2.MDD Treatment Landscape
EP: 3.Potential Consequences of Recurrent or Poorly Controlled MDD
EP: 4.Burden of Treatment Failure in MDD
EP: 5.Importance of Early Effective Treatment of MDD
EP: 6.Evaluating MDD Treatment Attributes
EP: 7.Considerations for Newly Launched MDD Treatments
EP: 8.Healthcare Disparities Within Major Depressive Disorder
EP: 9.MDD Treatment Disparities Across Patient Populations
EP: 10.Social Determinants of Health in MDD
EP: 11.Impact of COVID-19 on Demand for Mental Health Services
EP: 12.Health Care Disparities Within Major Depressive Disorder (MDD)
EP: 13.MDD Treatment Disparities Across Patient Populations: Part 2
EP: 14.Social Determinants of Health in MDD: Part 2
EP: 15.Population Health Approach in MDD
EP: 16.Factors Affecting MDD Treatment Adherence
EP: 17.Supporting Adherence for Patients with MDD
EP: 18.Aligning MDD Treatment Goals for Payers and Patients
EP: 19.The Impact of Early Effective Treatment in MDD
EP: 20.Key Contributors to Long-term Outcomes for Patients With MDD
H. Eric Cannon, PharmD, FAMCP: Money can’t solve all our problems, but it sure helps. Can you afford your co-pays? Poverty is definitely playing into this. Homeless people [are affected]. We’re starting to work with populations that have recently been discharged from prison. There are people who don’t feel accepted. That acceptance goes across a lot of levels. If I found a physician or a therapist, but I don’t feel accepted or I don’t feel that it’s an inclusive environment, I might not keep going. That plays a role in how a patient feels. Finding ways to be more inclusive is critical for all of us.
Michael Rothrock, MBA, MHA: This is a continuing theme of our last couple of topics. We’ve [spoken] about the socioeconomic status of individuals who are the most challenging to identify and get access and care to, based on their lower income levels. At the end of the day, it comes down to education, affordability, access to care, promotion, and awareness through the workforce and your own internal HR [human resources] departments to say that there are self-help opportunities and ways to get in touch with providers or caregivers to assist you if you or a family member are experiencing symptoms of depression.
This holistic approach becomes much more magnified, and we’re much more aware as a society. We went through 2-plus years of COVID-19, and we’re trying to find the best way to [reach] these patients on a regular basis, or at least provide them the help or care they need so they can invest in themselves. As Dr Cannon mentioned, affordability is one thing. If they can’t afford the co-pays, that’s going to be a challenge. But other ways of finding care through local communities—self-help books, manufacturer-sponsored programs, church groups, even your own colleagues and friends—is something we need to see as an opportunity to [reach] these patients more frequently.
Transcript edited for clarity.
Younger Patients With PV May Benefit From Earlier Treatment With Cytoreductive Therapies
March 27th 2024For most patients younger than age 60 with polycythemia vera (PV) who are not considered high risk, cytoreductive therapies are withheld despite being highly effective.
Read More
Updates on Adagrasib in CRC and the Importance of Genomic Testing With Dr Jun Gong
December 21st 2023Jun Gong, MD, of Cedars-Sinai Medical Center, discusses the latest data on adagrasib in colorectal cancer, the importance of conducting genomic testing, and more.
Listen
Pegylated Interferons Have Promise but Also Unmet Potential in MPNs
March 26th 2024Despite potential benefits, the therapy remains in limited use for myeloproliferative neoplasms (MPNs).
Read More
Managed Care Cast Presents: Insights Into Precision Medicine in NSCLC
November 30th 2023In this podcast, a trio of experts discuss precision medicine in non–small cell lung cancer (NSCLC), current immunotherapies, and more.
Listen
Dupilumab Reduces Asthma Symptoms Regardless of Exacerbation History, Study Finds
March 25th 2024Dupilumab significantly reduced the risk of exacerbations compared with placebo in children with moderate to severe asthma, regardless of exacerbation history.
Read More
Cetuximab Effective in Patients With CRC After Induction Chemotherapy
March 25th 2024A study found that cetuximab along or with chemotherapy was an effective option in patients with metastatic colorectal cancer (CRC).
Read More
Younger Patients With PV May Benefit From Earlier Treatment With Cytoreductive Therapies
March 27th 2024For most patients younger than age 60 with polycythemia vera (PV) who are not considered high risk, cytoreductive therapies are withheld despite being highly effective.
Read More
Updates on Adagrasib in CRC and the Importance of Genomic Testing With Dr Jun Gong
December 21st 2023Jun Gong, MD, of Cedars-Sinai Medical Center, discusses the latest data on adagrasib in colorectal cancer, the importance of conducting genomic testing, and more.
Listen
Pegylated Interferons Have Promise but Also Unmet Potential in MPNs
March 26th 2024Despite potential benefits, the therapy remains in limited use for myeloproliferative neoplasms (MPNs).
Read More
Managed Care Cast Presents: Insights Into Precision Medicine in NSCLC
November 30th 2023In this podcast, a trio of experts discuss precision medicine in non–small cell lung cancer (NSCLC), current immunotherapies, and more.
Listen
Dupilumab Reduces Asthma Symptoms Regardless of Exacerbation History, Study Finds
March 25th 2024Dupilumab significantly reduced the risk of exacerbations compared with placebo in children with moderate to severe asthma, regardless of exacerbation history.
Read More
Cetuximab Effective in Patients With CRC After Induction Chemotherapy
March 25th 2024A study found that cetuximab along or with chemotherapy was an effective option in patients with metastatic colorectal cancer (CRC).
Read More